FTC sues to block Omnicare's PharMerica offer; J&J recalls baby lotion on bacteria levels;

@FiercePharma: Manchester Evening News cites talk of 3,000 job cuts for $AZN. More | Follow @FiercePharma

> Omnicare's bid for rival pharmacy services company PharMerica has hit another obstacle, as the Federal Trade Commission sues to block the deal. News

> Johnson & Johnson ($JNJ) recalled one lot of Aveeno Baby Calming Comfort Lotion after FDA tests found a batch with higher-than-allowed concentrations of a naturally occurring bacteria. Report

> Novartis ($NVS) inked a deal with the World Health Organization to continue donating multi-drug therapy for leprosy treatment. Story

> India's Elder Pharma is linking up with Japanese distributors as it prepares to launch APIs in that country. Article

> Glenmark Pharmaceuticals saw fourth-quarter profits drop by nearly half on foreign-exchange losses, despite strong growth in product sales. News

> The Pharma Bureau in Pakistan has urged the government to set up a regulatory authority to oversee the drug industry, to ensure patient safety and to rebuild confidence as officials investigate recent deaths linked with potentially faulty heart pills. More

Biotech News

@FierceBiotech: BREAKING: Roche wins landmark approval for targeted skin cancer drug vismodegib. News | Follow @FierceBiotech

@JohnCFierce: Cell Therapeutics pulls its pixantrone app, presumably so they can keep saying how certain they are of an approval. Release | Follow @JohnCFierce

@RyanMFierce: An example of a DNA sequencing success in medicine where children of $LIFE employee benefited. Article | Follow @RyanMFierce

@MarkHFierce: Grape seed extract is the latest potential cancer drug. More | Follow @MarkHFierce

> Buzz: Is ax set to fall again on AstraZeneca R&D? Story

> 13 Big Pharmas to collaborate on $785M fight against neglected diseases. News

> FDA whistleblowers accuse agency of secretly reviewing email. Item

IT News

> Google Ventures, VCs backing tech focused on genomics. More

> U.K. genomics database plan faces hurdles. Story

> Covance's big IT budget gets thumbs down from analysts. Article

> Gamers tackle enzyme makeover, beat scientists' efforts. News

> Emerging player in DNA analysis joins forces with U. of Missouri. More

Medical Device News

> Abbott to cut 700 jobs as Promus sales decline. Story

> Roche's $5.7B Illumina bid risks standing alone. Article

> Covidien sees strength in medical device unit as profits rise. News

> KCI installs new CEO, chairman. More

And Finally... Political heat has forced U.K. Health Secretary Andrew Lansley to overhaul his proposed reforms for the National Health Service. Report

Suggested Articles

Monday, Bernstein analysts echoed what many were probably thinking about Novo Nordisk’s Rybselsus price: “Finally we can stop talking about it.”

Low interest rates and strong stock valuations are two top reasons why U.S. drugmakers are on the move for deals.

Despite a 45% premium offered to Allergan investors through the AbbVie buyout, one investor is suing to block the deal.